Chen CY, Lu CL, Luo JC, Chang FY, Lee SD, Lai YL. Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol 2005; 11(20): 3112-3117 [PMID: 15918199 DOI: 10.3748/wjg.v11.i20.3112]
Corresponding Author of This Article
Full-Young Chang, MD, Chief, Division of Gastroenterology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan, China. changfy@vghtpe.gov.tw
Article-Type of This Article
Clinical Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2005; 11(20): 3112-3117 Published online May 28, 2005. doi: 10.3748/wjg.v11.i20.3112
Table 1 Demographics and baseline characteristics of erosive esophagitis patients treated with esomeprazole or omeprazole (mean±SE).
Esomeprazole 40 mg n = 25
Omeprazole 20 mg n = 23
P
Age (yr)
49.2±3.7
59.0±3.4
0.0596
Sex (male%)
20 (80)
18 (78.3)
1.0000
Body weight (kg)
68.4±2.4
70.9±2.5
0.4779
Height (cm)
166.7±1.3
169.0±1.4
0.2096
Basal reflux symptoms (VAS)
Heartburn
29.4±5.7
23.6±5.9
0.2683
Nausea
18.7±5.5
13.8±5.8
0.8520
Regurgitation
29.8±6.1
24.5±6.4
0.3365
Vomiting
14.0±4.7
8.8±4.9
0.5702
Belching
47.0±6.0
25.2±6.3
0.0121
Dysphagia
7.5±5.0
14.7±5.2
0.7421
Epigastric pain
15.8±5.5
16.7±5.8
0.9223
LA grade of erosive esophagitis [n (%)]
0.6617
A
15 (60)
11 (47.8)
B
7 (28)
7 (30.4)
C
2 (8)
2 (8.7)
D
1 (4)
3 (13.0)
Hp infection status
10 (40)
11 (47.8)
0.5643
Table 2 Changes of reflux symptoms assessed on visual analog scale of studied patients 8 wk after esomeprazole or omeprazole treatment (mean±SE).
Reflux symptoms
Esomeprazole n = 22
Omeprazole n = 22
P
Heartburn
-22.3±2.1
-21.4±2.2
0.5453
Nausea
-11.9±2.2
-12.7±2.4
0.8867
Regurgitation
-22.4±2.2
-20.4±2.3
0.8598
Vomiting
-9.1±1.61
-8.8±1.7
0.4438
Belching
-24.1±4.3
-17.9±4.6
0.0113
Dysphagia
-8.4±1.4
-6.5±1.5
0.8044
Epigastric pain
-10.6±2.0
-11.1±2.1
0.1747
Table 3 Changed reflux symptoms of studied patients 8 wk after esomeprazole or omeprazole treatment (%).
Esomeprazole (n = 22)
Omeprazole (n = 20)
P
Heartburn
Improved
50.0
65.0
0.0993
No change
50.0
25.0
Worse
0.0
10
Regurgitation
Improved
77.3
85.0
1.0000
No change
18.2
15.0
Worse
4.5
0.0
Dysphagia
Improved
36.4
35.0
0.8697
No change
63.6
60.0
Worse
0.0
5
Epigastric pain
Improved
27.3
50.0
0.1895
No change
63.6
50.0
Worse
9.1
0.0
Nausea
Improved
22.7
35.0
0.5036
No change
68.2
65.0
Worse
9.1
0
Vomiting
Improved
22.7
40.0
0.3200
No change
77.3
60.0
Worse
0.0
0.0
Belching
Improved
54.5
45.0
0.8999
No change
36.4
45.0
Worse
9.1
10
Table 4 AE in studied patients 8 wk after esomeprazole or omeprazole treatment (ITT).
Esomeprazole (n = 25) n(%)
Omeprazole (n = 23) n (%)
P
Patient with at least one AE
7 (28.0)
6 (26.1)
1.0000
Constipation
2 (8.0)
1 (4.4)
1.0000
Dry skin
1 (4.0)
3 (13.0)
0.3381
Diarrhea
1 (4.0)
1 (4.4)
1.0000
Headache
1 (4.0)
1 (4.4)
1.0000
Somnolence
1 (4.0)
1 (4.4)
1.0000
Cellulites
0 (0.0)
1 (4.4)
0.4792
Bronchitis
0 (0.0)
1 (4.4)
0.4792
Citation: Chen CY, Lu CL, Luo JC, Chang FY, Lee SD, Lai YL. Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol 2005; 11(20): 3112-3117